Table 1 Statistical comparisons of the clinicopathological and molecular features of patients by methylation status of the MGMT promoter
Valid cases, tumours (%) | MGMT Meth (%) | MGMT Unmeth (%) | P-value | |
|---|---|---|---|---|
Clinicopathological tumour features | ||||
Mean age, years (±1 s.d.) | 68.9±12.2 | 70.4 (±12.6) | 68.3 (±12.0) | 0.012* |
Gender | 1123 (100) | |||
Female | 505 (45.0) | 167 (33.1) | 338 (66.9) | 0.000 |
Male | 618 (55.0) | 145 (23.5) | 473 (76.5) | |
Mucinous histology | 1119 (99.6) | |||
Mucinous | 230 (20.5) | 78 (33.9) | 152 (66.1) | 0.033 |
Non-mucinous | 889 (79.2) | 234 (26.3) | 655 (73.7) | |
IELs | 1122 (99.9) | |||
Conspicuous | 176 (15.7) | 64 (36.4) | 112 (63.6) | 0.018 |
Inconspicuous | 946 (84.2) | 248 (26.2) | 698 (73.8) | |
Lymphovascular space invasion | 1113 (99.1) | |||
Absent | 669 (59.6) | 213 (31.8) | 456 (68.2) | 0.001 |
Present | 444 (39.5) | 96 (21.6) | 348 (78.4) | |
Molecular features of tumour | ||||
Microsatellite status | 1121 (99.8) | |||
MSI | 146 (13.0) | 53 (36.3) | 93 (63.7) | 0.037 |
MSS | 975 (86.8) | 258 (26.5) | 717 (73.5) | |
CIMP status | 1120 (99.8) | |||
Positive | 156 (13.9) | 60 (38.5) | 96 (61.5) | 0.003 |
Negative | 964 (85.8) | 252 (26.1) | 712 (73.9) | |
BRAF mutation status | 1119 (99.6) | |||
V600E Mutant | 138 (12.3) | 49 (35.5) | 89 (64.5) | 0.047 |
Wild type | 981 (87.4) | 263 (26.8) | 718 (73.2) | |
KRAS mutation status | 1121 (99.9) | |||
Mutant | 358 (31.9) | 137 (38.3) | 221 (61.7) | 0.000 |
Wild type | 763 (68.0) | 175 (22.9) | 588 (77.1) | |
MLH1 methylation | 1101 (98.1) | |||
Methylated | 127(11.3) | 49 (38.6) | 78 (61.4) | 0.003 |
Unmethylated | 974 (86.8) | 261 (26.8) | 713 (73.2) | |
CDKN2A methylation | 1075 (95.7) | |||
Methylated | 481 (42.8) | 182 (37.8) | 299 (62.2) | 0.000 |
Unmethylated | 594 (52.9) | 126 (21.2) | 468 (78.8) | |
Patient genotype | ||||
SNP rs16906252 | 1039 (92.5) | |||
CT | 151 (13.4) | 91 (60.3) | 60 (39.7) | |
TT | 2 (0.2) | 2 (100) | 0 (0) | 0.000 |
CC | 886 (78.9) | 195 (22.0) | 691 (78.0) | |
